Cognetivity Neurosciences Ltd. announced a strategic partnership with CLAIRVO TECHNOLOGIES Inc. aimed at revolutionizing brain health and addressing dementia-related challenges in Japan. Leveraging the power of artificial intelligence (AI), this partnership seeks to enhance preventative care and promote healthy aging within the Japanese population. As part of the collaboration, Clairvo will join forces with Cognetivity.

Together, they aim to integrate CognICA into Clairvo's existing AI portfolio of health and wellness products, providing innovative cognitive monitoring capabilities to the Japanese population. By harnessing the potential of AI and cognitive assessment technologies, Clairvo and Cognetivity aim to empower individuals and healthcare professionals in early detection and continuous monitoring of cognitive health. This proactive approach will enhance the benefits of early intervention and personalized care, ultimately promoting brain health, well-being, and improved quality of life.

Earlier this year the US Food and Drug Administration (FDA) approved Lecanemab, a breakthrough drug to treat Alzheimer's, manufactured by Eisai Co Ltd, which requires early diagnosis to be effective.